 Nuvation Bio Inc NYSE:NUVB shares are trading higher after the company announced FDA clearance of its investigational new drug application for NUV-422. FDA clearance of our third IND application for NUV-422 is another important achievement for our lead investigational CDK 246 inhibitor program as we develop our deep pipeline of innovative new cancer therapeutics across a variety of tumor types, said David Hung, M.D. 